Full video transcriptClick to expand
Auto-generated transcript of @daviddemesquita's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00The best peptides I hope with anxiety and depression are C-Max and Slank.
- 0:04C-Max is going to help with sense of urgency to get stuff done and cognitive focus.
- 0:09In fact, this peptide has been used within stroke victims to help them with cognitive focus.
- 0:14We'll get into dosing here in a second. The other one is Slank. The horses are running around right now.
- 0:20So Slank works as a calming agent so people that are having anxiety, it works pretty effectively for.
- 0:27One thing that I do friends, I use pet horses. How you doing buddy?
- 0:31So when it comes to dosing on them, they're slightly different and you also don't want to take them together.
- 0:38With C-Max, it is 500 micrograms what I have found effective for me and most people.
- 0:47Some people don't need as much, some people need more.
- 0:50And this is done two to up to three times per day depending on what someone's needs are.
- 0:55When it comes to Slank, the dosing is slightly different and again you want them at least 30 minutes apart from each other
- 1:01because remember, when one drives up, your urgency to get stuff done and the other one calms you.
- 1:05Slank dosing is around 400 micrograms as needed and usually it's two times per day is the typical use.
- 1:13Now with C-Max, I was talking about stroke victims. Now stroke victims dosing goes up to 5 milligrams per day.
- 1:18So this should show how effective it is and how safe it is.
Selank and semax for depression and anxiety: hype vs. evidence
Quick answer
Semax and selank are synthetic peptides developed in Russia with preliminary evidence supporting nootropic and anxiolytic effects respectively, but neither has been reviewed or approved by the FDA for any condition. The dosing figures cited in the video appear drawn from Russian clinical literature and informal community use, not from standardized pharmacokinetic or dose-finding trials in U.S. or EU populations. Anyone with a clinical diagnosis of anxiety or depression should consult a licensed provider before considering either compound, as drug interactions, contraindications, and quality control risks remain poorly characterized outside controlled research settings.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 3 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Selank and semax for depression and anxiety: hype vs. evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Functional Connectomic Approach to Studying Selank and Semax Effects
Small Russian fMRI study (52 healthy volunteers) of brain connectivity after Semax or Selank; mechanistic and exploratory, not a clinical efficacy trial.
PubMed
Effects of Semax on the Default Mode Network of the Brain
Small human fMRI study (24 adults) of intranasal Semax on brain networks; an imaging-marker study with no clinical outcomes, not replicated outside the originating group.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Selank and semax for depression and anxiety: hype vs. evidence is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Selank and semax for depression and anxiety: hype vs. evidence" from David DeMesquita™️. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semax and selank are synthetic peptides developed in Russia with preliminary evidence supporting nootropic and anxiolytic effects respectively, but neither has been reviewed or approved by the FDA for any condition.
The reason this review is not generic is the source wording and the canonical claim label "peptides replying to justin bushovisky depression anxiety bodybuildin." In this clip, the useful excerpt is: "The best peptides I hope with anxiety and depression are C-Max and Slank." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Functional Connectomic Approach to Studying Selank and Semax Effects (2020), Effects of Semax on the Default Mode Network of the Brain (2018), and Therapeutic Peptides: Applications, Challenges, and Future Directions (2026), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semax and selank are synthetic peptides developed in Russia with preliminary evidence supporting nootropic and anxiolytic effects respectively, but neither has been reviewed or approved by the FDA for any condition.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semax and selank are synthetic peptides developed in Russia with preliminary evidence supporting nootropic and anxiolytic effects respectively, but neither has been reviewed or approved by the FDA for any condition. The dosing figures cited in the video appear drawn from Russian clinical literature and informal community use, not from standardized pharmacokinetic or dose-finding trials in U.S. or EU populations. Anyone with a clinical diagnosis of anxiety or depression should consult a licensed provider before considering either compound, as drug interactions, contraindications, and quality control risks remain poorly characterized outside controlled research settings.
- Neither semax nor selank is FDA-approved for any condition, including depression, anxiety, or cognitive enhancement. Both are research compounds in the United States.
- Semax is registered as a drug in Russia for stroke and cognitive impairment. Gusev et al. (1997) supports its use in ischemic stroke recovery, which is the one claim the creator made that has genuine published backing.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Neither semax nor selank is FDA-approved for any condition, including depression, anxiety, or cognitive enhancement. Both are research compounds in the United States.
- Semax is registered as a drug in Russia for stroke and cognitive impairment. Gusev et al. (1997) supports its use in ischemic stroke recovery, which is the one claim the creator made that has genuine published backing.
- Selank's anxiolytic effects are supported by limited human trials, including Semenova et al. (2010), but those trials involved small samples and were conducted in Russian clinical settings, limiting generalizability.
- The argument that high doses used in stroke patients prove general safety is logically flawed. Therapeutic context, monitoring, and patient population all affect what a dose tells us about risk.
- Route of administration matters. Intranasal and subcutaneous semax dosing produce different bioavailability profiles, and the video does not specify route, which makes the dose figures difficult to evaluate.
- Compounded or research-chemical versions of these peptides carry real purity and concentration risks. No regulatory body has verified the quality of products sold outside a licensed pharmacy framework.
- If you have a diagnosed mood disorder or are on psychiatric medications, consult a licensed clinician before using either peptide. Interaction data with antidepressants or anxiolytics is essentially nonexistent in published literature.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @daviddemesquita actually say?
The creator recommended two peptides, which he calls "C-Max" (semax) and "Slank" (selank), for anxiety and depression. He described semax as helping with "sense of urgency" and cognitive focus, citing use in stroke patients, and selank as a "calming agent" for anxiety. He suggested doses of 500 micrograms for semax, taken two to three times daily, and 400 micrograms of selank twice daily, with a 30-minute separation between the two. He used stroke dosing of up to 5 milligrams per day as evidence of both efficacy and safety.
To be clear about the names: these peptides are semax and selank, not "C-Max" and "Slank." The mispronunciation matters because people searching for these compounds need accurate terminology. The creator's general framing, that these are distinct peptides with opposite functional profiles, is roughly consistent with their pharmacological research backgrounds.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
David DeMesquita™️ · TikTok creator
66.6K views on this video
Replying to @Justin Bushovisky #depression #anxiety #bodybuilding #peptide
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about neither semax nor selank?
Neither semax nor selank is FDA-approved for any condition, including depression, anxiety, or cognitive enhancement. Both are research compounds in the United States.
What does the video say about semax?
Semax is registered as a drug in Russia for stroke and cognitive impairment. Gusev et al. (1997) supports its use in ischemic stroke recovery, which is the one claim the creator made that has genuine published backing.
What does the video say about selank's anxiolytic effects?
Selank's anxiolytic effects are supported by limited human trials, including Semenova et al. (2010), but those trials involved small samples and were conducted in Russian clinical settings, limiting generalizability.
What does the video say about the argument?
The argument that high doses used in stroke patients prove general safety is logically flawed. Therapeutic context, monitoring, and patient population all affect what a dose tells us about risk.
What does the video say about route of administration matters. intranasal?
Route of administration matters. Intranasal and subcutaneous semax dosing produce different bioavailability profiles, and the video does not specify route, which makes the dose figures difficult to evaluate.
What does the video say about compounded?
Compounded or research-chemical versions of these peptides carry real purity and concentration risks. No regulatory body has verified the quality of products sold outside a licensed pharmacy framework.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by David DeMesquita™️, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.